DOMINO trial post hoc analysis: evaluation of the diet effects on symptoms in IBS subtypes.

Autor:	Di Rosa C; Campus Bio-Medico University, Roma, Italy., Van den Houte K; Translational Research Center for Gastrointestinal Diseases (TARGID), Department of Chronic Diseases and Metabolism (ChroMeta), University of Leuven, Leuven, Belgium., Altomare A; Campus Bio-Medico University, Roma, Italy., Guarino MPL; Campus Bio-Medico University, Roma, Italy., Besard L; Department of Gastroenterology, University Hospital Leuven (UZ Leuven), Leuven, Belgium., Arts J; Department of Gastroenterology, Algemeen Ziekenhuis Sint Lucas, Brugge, Belgium., Caenepeel P; Hosptial Oost-Limburg, Genk, Belgium., Piessevaux H; Department of Gastroenterology and Hepatology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium., Vandenberghe A; BVBA, Chaumont-Gistoux, Belgium., Matthys C; Clinical and Experimental Endocrinology, Departments of Chronic Diseases and Metabolism, and Endocrinology, University Hospitals Leuven, Leuven, Belgium., Biesiekierski JR; Translational Research Center for Gastrointestinal Diseases (TARGID), Department of Chronic Diseases and Metabolism (ChroMeta), University of Leuven, Leuven, Belgium.; Department of Dietetics, Nutrition and Sport, La Trobe University, Melbourne, VIC, Australia., Capiau L; General Medicine Practice, Massemen, Belgium., Ceulemans S; General Medicine Practice, Beverst, Belgium., Gernay O; General Medicine Practice, Gent, Belgium., Jones L; General Medicine Practice, Rixensart, Belgium., Maes S; General Medicine Practice, Leuven, Belgium., Peetermans C; General Medicine Practice, Haacht, Belgium., Raat W; Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium., Stubbe J; General Medicine Practice, Oostende, Belgium., Van Boxstael R; General Medicine Practice, Betekom, Belgium., Vandeput O; General Medicine Practice, Tremelo, Belgium., Van Steenbergen S; General Medicine Practice, Berchem, Belgium., Van Oudenhove L; Translational Research Center for Gastrointestinal Diseases (TARGID), Department of Chronic Diseases and Metabolism (ChroMeta), University of Leuven, Leuven, Belgium., Vanuytsel T; Translational Research Center for Gastrointestinal Diseases (TARGID), Department of Chronic Diseases and Metabolism (ChroMeta), University of Leuven, Leuven, Belgium.; Department of Gastroenterology, University Hospital Leuven (UZ Leuven), Leuven, Belgium., Jones M; Faculty of Human Sciences, Macquarie University, Sydney, NSW, Australia.; Claudia Di Rosa and Annamaria Altomare are also affiliated to Research Unit of Food Science and Human Nutrition, Department of Science and Technology for Sustainable Development and One Health, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo, 21 - 00128 Roma, Italy., Tack J; Translational Research Center for Gastrointestinal Diseases (TARGID), University Hospital Gasthuisberg, O&N I - Bus 701, Herestraat 49, Leuven B-3000, Belgium.; Department of Gastroenterology, University Hospital Leuven (UZ Leuven), Leuven, Belgium.; Institute of Medicine, University of Gothenburg, Gothenburg, Sweden., Carbone F; Translational Research Center for Gastrointestinal Diseases (TARGID), Department of Chronic Diseases and Metabolism (ChroMeta), University of Leuven, Leuven, Belgium.; Department of Gastroenterology, University Hospital Leuven (UZ Leuven), Leuven, Belgium.
Jazyk:	angličtina
Zdroj:	Therapeutic advances in gastroenterology [Therap Adv Gastroenterol] 2024 Jul 30; Vol. 17, pp. 17562848241255296. Date of Electronic Publication: 2024 Jul 30 (Print Publication: 2024).
DOI:	10.1177/17562848241255296
Abstrakt:	Background: Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction characterized by recurrent abdominal pain related to defecation and/or associated to a change in bowel habits. According to the stool type, four different IBS subtypes can be recognized, constipation predominant (IBS-C), diarrhea predominant (IBS-D), mixed (IBS-M), and undefined (IBS-U). Patients report that their IBS symptoms are exacerbated by food. Thus, it is important to find a nutritional approach that could be effective in reducing IBS symptoms. Objective: The present work is a post hoc analysis of the previously published DOMINO trial. It aimed to evaluate the effects of a self-instructed FODMAP-lowering diet smartphone application on symptoms and psychosocial aspects in primary care IBS stratifying the results for each IBS subtypes. Design: Post hoc analysis. Methods: Two hundred twenty-two primary care IBS patients followed a FODMAP-lowering diet for 8 weeks with the support of a smartphone application. Two follow-up visits were scheduled after 16 and 24 weeks. IBS-Symptoms Severity Score (IBS-SSS), quality of life (QoL), and adherence and dietary satisfaction were evaluated. Results: After 8 weeks, IBS-SSS improved in all IBS subtypes ( p  < 0.0001). Physician Health Questiionnaire (PHQ-15) improved only in IBS-D ( p  = 0.0006), whereas QoL improved both in IBS-D ( p  = 0.01) and IBS-M ( p  = 0.005). Conclusion: This post hoc analysis showed that the app is useful in all IBS subtypes; thus, it could be used as an effective tool by both general practitioners and patients to manage symptoms in primary care. Trial Registration: Ethical Commission University Hospital of Leuven reference number: S59482. Clinicaltrial.gov reference number: NCT04270487. Competing Interests: Jan Tack has given Scientific advice to AlfaWassermann, Allergan, Christian Hansen, Danone, Grünenthal, Ironwood, Janssen, Kiowa Kirin, Menarini, Mylan, Neutec, Novartis, Noventure, Nutricia, Shionogi, Shire, Takeda, Theravance, Tramedico, Truvion, Tsumura, Zealand and Zeria pharmaceuticals, has received research support from Shire, Sofar and Tsumura, and has served on the Speaker bureau for Abbott, Allergan, AstraZeneca, Janssen, Kyowa Kirin, Menarini and Karen PDM. Christophe Matthys has served on the Speaker bureau for Coca-Cola and Zespri and received travel/conference grants from Danone, Nestlé Health Sciences, Fresenius-Kabi. This study was supported by a research grant from the Belgian Health Care Knowledge Centre (KCE). Questionnaires in this trial were developed, translated, and provided by the Rome Foundation Research Institute. (© The Author(s), 2024.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu